Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Prediction Based on HPV DNA Testing by Hybrid Capture 2 (HC2) in Combination with Liquid-based Cytology (LBC)

  • Junyangdikul, Pairoj (Department of Pathology, Samitivej Srinakharin Hospital, Bangkok Hospital Group Thailand) ;
  • Tanchotsrinon, Watcharaporn (Advanced Virtual and Intelligent Computing (AVIC) Center, Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University) ;
  • Chansaenroj, Jira (Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Nilyaimit, Pornjarim (Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University) ;
  • Lursinsap, Chidchanok (Advanced Virtual and Intelligent Computing (AVIC) Center, Department of Mathematics and Computer Science, Faculty of Science, Chulalongkorn University) ;
  • Poovorawan, Yong (Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University)
  • Published : 2013.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Primary screening by HPV DNA testing is an effective method for reducing cervical cancer and has proven more sensitive than cytology. To advance this approach, many molecular methods have been developed. Hybrid capture 2 provides semi-quantitative results in ratios of relative light units and positive cutoff values (RLU/PC). Twenty-five thousand and five patients were included in this study to analyze the correlation between the ratio of RLU/PC and stage of cervical dysplasia. The results show that the RLU/PC ratios ranged from 0-3500 while almost normal cases, ASC-US and ASC-H, had values below 200. Of those samples negative for cytology markers, 94.6% were normal and their RLU/PC ratios were less than 4. With an RLU/PC ratio greater than 4 and less than or equal to 300, the percentages in all age groups were normal 53.6%, LSIL 20.2%, ASC-US 17.2%, HSIL 6.13%, ASC-H 2.72%, and AGC 0.11%, respectively. In contrast, 64.0% of samples with a RLU/PC ratio greater than 300 and less than or equal to 3500 were LSIL. These results should contribute to cost effective cervical cancer management strategies. Further studies of associations with particular HPV genotypes would be useful to predict the risk of progression to cancer.

Keywords

References

  1. ASCUS-LSIL Triage Study (ALTS) Group (2003). Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol, 188, 1383-92. https://doi.org/10.1016/S0002-9378(03)00418-6
  2. Belinson JL, Wu R, Belinson SE, et al (2011). A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol, 135, 790-5. https://doi.org/10.1309/AJCPKA6ATAPBZ6JQ
  3. Bhatla N, Moda N (2009). The clinical utility of HPV DNA testing in cervical cancer screening strategies. Indian J Med Res, 130, 261-5.
  4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65. https://doi.org/10.1136/jcp.55.4.244
  5. Bozzetti M, Nonnenmacher B, Mielzinska II, et al (2001). Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann Epidemiol, 10, 466.
  6. Canadas MP, Cirigliano V, Darwich L, et al (2012). Comparison of the f-HPV $typing^{TM}$ and Hybrid $Capture II^{(R)}$ assays for detection of high-risk HPV genotypes in cervical samples. J Virol Methods, 183, 14-8. https://doi.org/10.1016/j.jviromet.2012.03.005
  7. Carestiato FN, Silva KC, Dimetz T, et al (2006). Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Br J Infectious Diseases, 10, 331-6.
  8. Castle PE, Schiffman M, Burk RD, et al (2002). Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol Biomarkers Prev, 11, 1394-9.
  9. Castle PE, Solomon D, Wheeler CM, et al (2008). Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol, 46, 2595-604. https://doi.org/10.1128/JCM.00824-08
  10. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006). Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine, 24, 26-34.
  11. Comar M, Iannacone MR, Casalicchio G, et al (2012). Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol, 50, 4041-6. https://doi.org/10.1128/JCM.02105-12
  12. Federschneider JM, Yuan L, Brodsky J, et al (2004). The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol, 191, 757-61. https://doi.org/10.1016/j.ajog.2004.03.077
  13. Forslund O, Antonsson A, Edlund K, et al (2002). Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol, 66, 535-41. https://doi.org/10.1002/jmv.2178
  14. Giorgi RP, Bisanzi S, Paganini I, et al (2010). Prevalence of HPV high and low risk types in cervical samples from the Italian general population: a population based study. BMC Infectious Diseases, 10, 214.
  15. Iftner T, Villa LL (2003). Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr, 31, 80-8.
  16. Kurian EM, Caporelli ML, Baker S, et al (2011). Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am J Clin Pathol, 136, 808-16. https://doi.org/10.1309/AJCPCQD7B7DPVHLH
  17. Lee GY, Kim SM, Rim SY, et al (2005). Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. Int J Gynecol Cancer, 15, 81-7.
  18. Menzo S, Ciavattini A, Bagnarelli P, et al (2008). Molecular epidemiology and pathogenic potential of underdiagnosed human papillomavirus types. BMC Microbiol, 8, 112. https://doi.org/10.1186/1471-2180-8-112
  19. Molijn A, Kleter B, Quint W, van Doorn LJ (2005). Molecular diagnosis of human papillomavirus (HPV) infections. J Clinical Virology, 32, 43-51. https://doi.org/10.1016/j.jcv.2004.12.004
  20. Munoz N, Bosch FX, de Sanjose S, et al (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27. https://doi.org/10.1056/NEJMoa021641
  21. Nanda K, McCrory DC, Myers ER, et al (2000). Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Annals of Internal Med, 132, 810-9. https://doi.org/10.7326/0003-4819-132-10-200005160-00009
  22. Nishino HT, Tambouret RH, Wilbur DC (2011). Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology. Cancer Cytopathol, 119, 219-27. https://doi.org/10.1002/cncy.20161
  23. Nunez-Troconis J, Delgado M, Gonzalez J, et al (2009). Human papillomavirus false positive cytological diagnosis in low grade squamous intraepithelial lesion. Invest Clin, 50, 447-54.
  24. Ogilvie GS, Cook DA, Taylor DL, et al (2013). Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada. Vaccine, 31, 1129-33. https://doi.org/10.1016/j.vaccine.2012.09.085
  25. Peyton CL, Schiffman M, Lorincz AT, et al (1998).Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol, 36, 3248-54.
  26. Ronco G, Cuzick J, Segnan N, et al (2007). HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer, 43, 476-80. https://doi.org/10.1016/j.ejca.2006.11.013
  27. Schiffman M, Castle PE (2003). Human papillomavirus: Epidemiology and public health. Arch Pathol Lab Med, 127, 930-4.
  28. Seme K, Fujs K, Kocjan BJ, Poljak M (2006). Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA Test using polymerase chain reaction and genotyping. J Virol Methods, 134, 252-6. https://doi.org/10.1016/j.jviromet.2005.12.004
  29. Terry G, Ho L, Londesborough P, et al (2001). Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol, 65, 155-62. https://doi.org/10.1002/jmv.2015
  30. Thrall MJ, Smith DA, Mody DR (2009). Women $\geq$30 years of age with low grade squamous intraepithelial lesion (LSIL) have low positivity rates when cotested for high-risk human papillomavirus: should we reconsider HPV triage for LSIL in older women? Diagn Cytopathol, 38, 407-12.
  31. Tsao KC, Huang CG, Kuo YB, et al (2010). Prevalence of human papillomavirus genotypes in northern Taiwanese women. J Med Virol, 82, 1739-45. https://doi.org/10.1002/jmv.21870
  32. Tsiodras S, Georgoulakis J, Chranioti A, et al (2010). Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer, 10, 53. https://doi.org/10.1186/1471-2407-10-53

Cited by

  1. Development of In-House Multiplex Real Time PCR for Human Papillomavirus Genotyping in Iranian Women with Cervical Cancer and Cervical Intraepithelial Neoplasia vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6257
  2. Population-based Cervical Cancer Screening Using High-risk HPV DNA Test and Liquid-based Cytology in Northern Thailand vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6837
  3. CCNA1 Promoter Methylation: a Potential Marker for Grading Papanicolaou Smear Cervical Squamous Intraepithelial Lesions vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7971
  4. Performance of HPV DNA Testing with Hybrid Capture 2 in Triaging Women with Minor Cervical Cytologic Abnormalities (ASC-US/LSIL) in Northern Thailand vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10961
  5. Manual Liquid Based Cytology for Pap Smear Preparation and HPV Detection by PCR in Pakistan vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.579
  6. Cervical cancer screening by molecular Pap-transformation of gynecologic cytology pp.87551039, 2018, https://doi.org/10.1002/dc.24116